228 related articles for article (PubMed ID: 34656143)
21. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].
Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041
[TBL] [Abstract][Full Text] [Related]
22. Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma.
Tuna M; Mills GB; Amos CI
Neoplasia; 2023 Nov; 45():100932. PubMed ID: 37801862
[TBL] [Abstract][Full Text] [Related]
23. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
[TBL] [Abstract][Full Text] [Related]
24. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
25. The PI3K/AKT/c-MYC Axis Promotes the Acquisition of Cancer Stem-Like Features in Esophageal Squamous Cell Carcinoma.
Zhang HF; Wu C; Alshareef A; Gupta N; Zhao Q; Xu XE; Jiao JW; Li EM; Xu LY; Lai R
Stem Cells; 2016 Aug; 34(8):2040-51. PubMed ID: 27144349
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of CCT3 predicts poor prognosis and promotes cell proliferation via inhibition of ferroptosis and activation of AKT signaling in lung adenocarcinoma.
Wang K; He J; Tu C; Xu H; Zhang X; Lv Y; Song C
BMC Mol Cell Biol; 2022 Jun; 23(1):25. PubMed ID: 35773623
[TBL] [Abstract][Full Text] [Related]
27. The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases.
Liang Y; Lei Y; Du M; Liang M; Liu Z; Li X; Gao Y
J Cell Mol Med; 2021 Jul; 25(14):7039-7051. PubMed ID: 34117717
[TBL] [Abstract][Full Text] [Related]
28. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
29. Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in
Shi R; Li M; Raghavan V; Tam S; Cabanero M; Pham NA; Shepherd FA; Moghal N; Tsao MS
Clin Cancer Res; 2018 Dec; 24(23):5990-6000. PubMed ID: 30093452
[TBL] [Abstract][Full Text] [Related]
30. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
[TBL] [Abstract][Full Text] [Related]
31. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.
Mao G; Mu Z; Wu DA
Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1484-1494. PubMed ID: 34605863
[TBL] [Abstract][Full Text] [Related]
32. Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer.
Thaiparambil J; Dong J; Grimm SL; Perera D; Ambati CSR; Putluri V; Robertson MJ; Patel TD; Mistretta B; Gunaratne PH; Kim MP; Yustein JT; Putluri N; Coarfa C; El-Zein R
Cancer Med; 2023 Jan; 12(1):584-596. PubMed ID: 35676822
[TBL] [Abstract][Full Text] [Related]
33. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
[TBL] [Abstract][Full Text] [Related]
34. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
[TBL] [Abstract][Full Text] [Related]
35. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis.
Zhang LX; Gao J; Long X; Zhang PF; Yang X; Zhu SQ; Pei X; Qiu BQ; Chen SW; Lu F; Lin K; Xu JJ; Wu YB
Mol Cancer; 2022 May; 21(1):110. PubMed ID: 35525959
[TBL] [Abstract][Full Text] [Related]
36. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
[TBL] [Abstract][Full Text] [Related]
37. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
38. What's the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients.
Wang W; Liu H; Li G
Front Endocrinol (Lausanne); 2022; 13():947443. PubMed ID: 36105402
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of HE4 suppresses tumor growth and invasiveness in lung adenocarcinoma through regulation of EGFR signaling.
Zhang Y; Yang W; Han X; Qiao Y; Wang H; Chen T; Li T; Ou WB
Oncol Res; 2024; 32(6):1119-1128. PubMed ID: 38827327
[TBL] [Abstract][Full Text] [Related]
40. Cancer/testis antigen LDHC promotes proliferation and metastasis by activating the PI3K/Akt/GSK-3β-signaling pathway and the in lung adenocarcinoma.
Chen L; Wu Q; Xu X; Yang C; You J; Chen F; Zeng Y
Exp Cell Res; 2021 Jan; 398(2):112414. PubMed ID: 33301764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]